A Phase 1/2a Study of VS-7375
Phase 1/2
330
about 3.3 years
18+
12 sites in CA, MA, MD +9
About this study
Researchers are testing the safety and effectiveness of a treatment called VS-7375 in adults with advanced solid tumors that have a KRAS G12D mutation. The trial will last approximately 1194 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Carboplatin + Pemetrexed + Pembrolizumab
- 2.Take Cetuximab
- 3.Take Gemcitabine
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carboplatin, cetuximab, gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), pemetrexed
injection (Injection), infusion
Primary: Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375, Part A: To identify the MTD or MFD, Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.
Secondary: Part A: To characterize the PK of VS-7375 as 2L+ monotherapy administered on a daily oral schedule, Part C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxel PK, Parts B and D: To characterize the safety, tolerability, and AE profile of the recommended VS-7375 regimens from Part A and Part C, Parts B, C, and D: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapies
Oncology